Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 10.03 as of 2026-10-06T18:31:41.454Z.
Consensus retrieved: 2026-10-06T12:26:45.894Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:31:41.454Z.
Quote observation: 2026-10-06T18:30:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 219fbb4d6b0ca624999def179c3978493f715f11796d6849d3f6b20cded99b3d
Forward PE Ratio (10.03) = Dated Quote Price ($39.55) / Consensus Forward EPS ($3.94)
FORWARD PE RATIO
10.03
SECTOR MEDIAN · HEALTHCARE
19.91
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
-49.62%
vs the sector median at left
Harmony Biosciences Holdings, Inc.
Market Cap
$2.29B
Forward PE Ratio
10.03
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | $2.29B | 10.03 |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 30.91 |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.33B | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.24B | N/A |
| Liquidia Corporation (LQDA)vs › | $2.34B | 10.58 |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.34B | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.37B | 12.81 |
| Pharvaris N.V. (PHVS)vs › | $2.18B | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | 82.67 |
Trailing P/E
12.8
reported TTM EPS
Forward P/E
10.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.94 implies +27.9% EPS growth vs the reported trailing $3.08.
At the dated quote price of $39.55, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.94 | $3.54 – $4.63 | 6 | 10.0x |
| 2027-12-31 | $4.32 | $3.58 – $4.99 | 6 | 9.2x |
| 2028-12-31 | $4.94 | $3.49 – $6.20 | 10 | 8.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
